Eli Lilly (LLY) delivered a second-quarter performance robust enough to shift the narrative surrounding its stock. For months, investors fixated on a sluggish U.S. launch for its new oral obesity pill, Foundayo. That concern hasn’t vanished, but Bank of America analysts argue it’s no longer the dominant driver. Instead, BofA points to a massive, underappreciated opportunity: the international obesity market.
Why BofA Raised Its Price Target on LLY
Bank of America lifted its price objective on Eli Lilly to $1,344 from $1,334, maintaining a 28.5x multiple on updated 2027 underlying earnings estimates. The bank justifies this premium valuation because Lilly is expanding faster than its large-cap pharmaceutical peers. The catalyst was a Q2 beat: revenue surged 48% year-over-year to $23.0 billion, with adjusted EPS of $8.38 crushing the $6.01 consensus. Management also raised full-year revenue guidance to $85–$87 billion.
The International Obesity Opportunity
BofA’s central thesis is that GLP-1 sales outside the United States are rapidly approaching parity with domestic sales. Mounjaro (tirzepatide) demonstrated this momentum last quarter, growing 55% in Europe, 30% in Japan, and 93% in China. The bank notes that most major countries have far larger pools of untreated obesity and diabetes patients than the U.S., implying a longer runway for volume growth abroad.
Foundayo’s Global Launch Is the Real Swing Factor
The oral GLP-1 pill Foundayo is the clearest catalyst. While its U.S. debut brought in $98 million (slightly below the ~$103 million estimate), BofA estimates roughly 60% of Foundayo’s peak sales will come from international markets. Lilly has filed for approval in over 40 countries and plans an overseas rollout in early 2027. Both Lilly and rival Novo Nordisk (NVO) report strong pent-up demand for oral options abroad, where injectable supply constraints have limited access.
Medicare Bridge Program Expands Domestic Base
On July 1, Medicare’s GLP-1 Bridge program launched, extending obesity-drug coverage to roughly 20 million eligible beneficiaries. Early feedback indicates smooth access, with most new patients being treatment-naïve. This widens the paying customer base domestically, even as U.S. net pricing trends lower—BofA pegged Q2 net sales at ~$580 per prescription, down 15% year-over-year but flat sequentially. Lilly management argues volume growth is outpacing price erosion.
Pipeline Depth Provides Optionality
Beyond Foundayo, BofA highlights two late-stage assets that extend Lilly’s franchise:
- Retatrutide: A next-generation triple-hormone agonist showing weight loss approaching bariatric surgery levels in Phase 3; U.S. filing planned for Q1 2027.
- Eloralintide: An amylin-based drug recently added to BofA’s model, underscoring pipeline depth.
What Investors Should Watch
LLY closed at $1,192.52 (near its 52-week high of $1,249.45), implying ~13% upside to BofA’s target. However, the stock trades at a P/E near 40, pricing in substantial future growth. Key risks: a single weak quarter on volume or pricing could trigger a sharp pullback, and the international Foundayo launch doesn’t begin in earnest until early 2027.
FAQ
1. Why does Bank of America believe the international obesity market could surpass the U.S.?
BofA cites faster GLP-1 sales growth in Europe, Japan, and China, combined with larger untreated patient populations in most major countries compared to the U.S., giving Eli Lilly a longer volume-growth runway abroad.
2. What is Foundayo and why is its international launch more important than its U.S. debut?
Foundayo is Eli Lilly’s oral GLP-1 pill for obesity. While its U.S. launch was modest ($98M), BofA estimates ~60% of its peak sales will come from over 40 international markets where injectable supply limits create pent-up demand for a pill.
3. How does the Medicare Bridge program affect Eli Lilly’s U.S. sales outlook?
The program opens GLP-1 coverage to ~20 million Medicare beneficiaries, creating a new wave of treatment-naïve patients. This supports volume growth even as net pricing per prescription declines through cash-pay and Bridge channels.
